ストックスクリーナーアプリを入手
18.09
1.40%
0.25
アフターアワーズ：
18.11
0.02
+0.11%
前日終値:
$17.84
開ける：
$17.89
24時間の取引高:
150.33K
Relative Volume:
0.38
時価総額：
$999.94M
収益：
$29.71M
当期純損益:
$-69.15M
株価収益率:
-35.26
EPS:
-0.513
ネットキャッシュフロー:
$-52.28M
1週間 パフォーマンス:
+6.54%
1か月 パフォーマンス:
-4.74%
6か月 パフォーマンス:
+48,529%
1年 パフォーマンス:
+48,529%
1日の値動き範囲:
$17.75
$18.16
1週間の範囲:
$16.10
$18.16
52週間の値動き範囲:
$14.72
$29.16
Aktis Oncology Inc Stock (AKTS) Company Profile
Compare AKTS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AKTS
Aktis Oncology Inc
|
18.09 | 986.12M | 29.71M | -69.15M | -52.28M | -0.513 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aktis Oncology Inc Stock (AKTS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-09 | 開始されました | H.C. Wainwright | Buy |
| 2026-02-03 | 開始されました | BofA Securities | Buy |
| 2026-02-03 | 開始されました | JP Morgan | Overweight |
| 2026-02-03 | 開始されました | Leerink Partners | Outperform |
| 2026-02-03 | 開始されました | TD Cowen | Buy |
| 2024-01-04 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-09-06 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2023-01-24 | 開始されました | B. Riley Securities | Buy |
| 2021-02-02 | 繰り返されました | Craig Hallum | Buy |
| 2021-01-15 | 繰り返されました | Craig Hallum | Buy |
| 2019-09-18 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2019-07-10 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2019-05-13 | 繰り返されました | Craig Hallum | Buy |
| 2019-02-05 | 繰り返されました | Craig Hallum | Buy |
| 2019-02-05 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2018-12-18 | 開始されました | Craig Hallum | Buy |
| 2018-11-30 | 開始されました | Lake Street | Buy |
| 2018-06-22 | 開始されました | Loop Capital | Buy |
| 2018-02-09 | 開始されました | Drexel Hamilton | Buy |
すべてを表示
Aktis Oncology Inc (AKTS) 最新ニュース
Top Cybin (HELP) Competitors 2026 - MarketBeat
H.C. Wainwright Raises its Price Target on Aktis Oncology (AKTS) to $33 - Insider Monkey
5 Healthcare Stocks Insiders Are Buying - Insider Monkey
Biopharma IPOs Had Their Best Showing In More Than A Year In Q1 - Citeline News & Insights
AMPH Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aktis Oncology, Inc.: Fundamental Analysis and Financial Ratings | AKTS | US01021M1045 - marketscreener.com
Aktis Oncology: Accelerated Pipeline Progress and High-Value Clinical Catalysts Underpin Buy Rating and $34 Target - TipRanks
Aktis Oncology (AKTS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $AKTS - MarketBeat
Aktis Oncology’s AKY-2519 gains IND approvals - BioWorld MedTech
H.C. Wainwright raises Akoustis Technologies price target on pipeline progress - Investing.com Canada
AKTS: Analyst Raises Price Target, Maintains 'Buy' Rating | AKTS Stock News - GuruFocus
FDA clears Aktis Oncology’s AKY-2519 for phase 1b trial By Investing.com - Investing.com Australia
Aktis Oncology (NASDAQ: AKTS) secures IND clearances and multi-year cash runway - Stock Titan
AKTS: Strong cash position post-IPO and Eli Lilly deal supports clinical pipeline through 2029 - TradingView
Aktis Oncology (NASDAQ: AKTS) outlines miniprotein alpha radiopharma strategy - Stock Titan
Aktis Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment - marketscreener.com
FDA clears Aktis Oncology’s AKY-2519 for phase 1b trial - Investing.com
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results - The Manila Times
Aktis Oncology Announces FDA Clearance of Investigational - GlobeNewswire
This Aktis Oncology analyst begins coverage on a bullish note; here are top 5 initiations for Monday - MSN
USA Stocks: Research Stocks from USA Stock Market - GuruFocus
AKTS (Aktis Oncology) PB Ratio : (As of Mar. 26, 2026) - gurufocus.com
Aktis Oncology, Inc.(NasdaqGS: AKTS) added to S&P TMI Index - MarketScreener
Aktis Oncology, Inc.(NasdaqGS: AKTS) added to Russell 3000E Value Benchmark - marketscreener.com
Aktis Oncology, Inc.(NasdaqGS: AKTS) added to Russell 3000E Growth Index - marketscreener.com
Huge insider buying now at this insurance giant and 2 biotechs - msn.com
Aktis Oncology (AKTS) Stock Analysis Report | Financials & Insights - Benzinga Japan
Little-known Cambridge firm plans public debut to fund pancreatic cancer trial - The Business Journals
Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX), Contineum Therapeutics, Inc. Class A (CTNM) and Aktis Oncology, Inc. (AKTS) - The Globe and Mail
AKTS: Innovative radiopharmaceutical platform advances with strong pipeline, partnerships, and cash runway - TradingView
AKTS: Innovative radiopharmaceutical platform targets major cancer types, backed by strong pipeline and funding - TradingView
This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Aktis Oncology Fast Track Win Highlights AKY-1189 Potential And Key Risks - Sahm
Assessing Aktis Oncology (AKTS) Valuation After Recent Share Price Momentum And Ongoing Losses - Sahm
Aktis Oncology, Inc. (AKTS) Presents at TD Cowen 46th Annual Health Care ConferenceSlideshow - Seeking Alpha
Aktis Oncology’s NECTINIUM-2 Trial: A New Radiopharma Bet in Solid Tumors - TipRanks
AKTS: New miniprotein radiopharmaceuticals target broad solid tumor markets, advancing in clinic - TradingView
AKTS: Lead radiopharmaceutical assets advance toward major milestones in a rapidly expanding market - TradingView
BUDA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
AKTS Technical Analysis & Stock Price Forecast - Intellectia AI
Generate Biomedicines shares fall in weak Nasdaq debut for drug developer - Reuters
Assessing Aktis Oncology (AKTS) Valuation As Shares Show Short Term Momentum Rebound - Yahoo Finance
Aktis Oncology: Fast-Track Momentum and Pipeline Catalysts Underpin Buy Rating and $34 Price Target - TipRanks
Aktis Oncology to Present at Upcoming March Investor Conferences - The Manila Times
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate - Bitget
Aktis Oncology receives U.S. FDA fast track designation for Aky-1189 - marketscreener.com
IPO Tracker 2026: Generate’s IPO Could Reach $425M, Largest Raise Yet - BioSpace
Aktis Oncology Inc (AKTS) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):